Morning Overview on MSN

The FDA approved Anktiva as the first treatment for one BCG-resistant form of bladder cancer

On October 14, the U.S. Food and Drug Administration announced that Anktiva (nogapendekin alfa inbakicept-pmln), used ...
BIOENGINEER

Bladder Cancer Study Challenges WHO’s 5% Rule for Grading Mixed Tumors

A study of 180 bladder tumors finds that survival drops only when the high-grade component exceeds 27.5 percent, far above ...
Blockonomi

ImmunityBio, Inc. (IBRX) Stock: Slides 7.25% Despite Major Breakthrough in Bladder Cancer Treatment

ImmunityBio (IBRX) stock fell 7.25% to $9.27 despite ANKTIVA trial results showing a 71% response rate and lasting benefits ...

IBRX Stock Rallies After FDA Clears Broader Anktiva Use In Bladder Cancer Months Ahead Of Deadline

FDA approved the drug Anktiva for adults with high-grade papillary-only non-muscle invasive bladder cancer that has not ...
Mens Fitness on MSN

New FDA Approval Aims to Help Patients Avoid Bladder Removal Surgery

The decision gives certain patients whose cancer has resisted BCG therapy another treatment option aimed at preserving the bladder. Here’s who qualifies and what the evidence shows.
CURE

Anktiva for Papillary Bladder Cancer: What Patients Should Know

Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, ...
PharmTech

Bladder Cancer: FDA Expands Anktiva Without a New Trial

On October 14, 2026, the FDA expanded the approved use of Anktiva (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guérin (BCG), to include adults with high-grad ...
Stanford Medicine

Urine test may improve bladder cancer diagnosis and guide treatment decisions

Researchers developed a urine test that detects bladder cancer, predicts which patients will benefit from immunotherapy ...
Health and Me on MSN

FDA approves new treatment option for bladder cancer unresponsive to standard immunotherapy

The US Food and Drug Administration recently approved an alternative treatment option for patients with BCG-unresponsive high ...
Healio

FDA expands Anktiva immunotherapy approval for BCG-unresponsive bladder cancer

The FDA expanded approval of Anktiva for bladder cancer. The agent is the first approved treatment for BCG-unresponsive, high ...

How Investors May Respond To CG Oncology (CGON) Hiring a CCO Before Potential Bladder Cancer Launch

In October 2026, CG Oncology appointed Isabel Kalofonos as Chief Commercial Officer, tasking her with leading commercial ...

FDA Expands Indication for ImmunityBio's Bladder Cancer Drug

The Food and Drug Administration has expanded its approved indication for ImmunityBio's Anktiva, a bladder-cancer treatment. The new indication expands Anktiva to be used in combination with Bacillus ...